clinical trial · NCT07528053
A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants
Shanghai Argo Biopharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 24
HVBW-20805BW-20805BW-20805-2
brief summary
A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants
started
Apr 28, 2026
primary completion
Jun 30, 2026
completion
Nov 5, 2027
last updated
Apr 21, 2026
detailed description
A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants
official title
A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol